Nonclinical precedent Request an invite

Viltepso: genotox, carcinogenicity and repro: done or skipped?

viltolarsen · DMD exon 53 (PMO)
Genotoxicity
Conducted; negative (Ames, CHL chromosomal aberration, mouse micronucleus)
“Viltolarsen was negative in a standard battery of in vitro (Ames, chromosomal aberration in CHL cells) and in vivo (mouse micronucleus) assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 5Source ↗
Carcinogenicity
Not conducted pre-approval (agreed); rasH2 mouse and 2-year rat studies as PMRs
“Carcinogenicity studies of viltolarsen were not submitted to the NDA, as agreed to by the Division.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Male mouse fertility study only (no effects); EFD/PPND waived for male population; juvenile mouse study
“Embryofetal development and pre- and postnatal development studies were not conducted, as agreed to by the Division, because of the intended patient population, which is almost exclusively male.”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
Safety pharmacology
Dedicated single-dose studies: rat CNS (FOB), monkey CV/respiratory, in vitro hERG; no effects
“Dedicated single dose studies in rat (CNS) and monkey (cardiovascular and respiratory) did not indicate drug effects on safety pharmacology endpoints, and there was no effect on QT prolongation in CHO cell cultures exposed to up to 3 mg/mL vitolarsen.”
✓ VerifiedFDA pharmacology/toxicology review, p. 47Source ↗
Genotox: Ames
Negative
“Viltolarsen was negative for genotoxicity in in vitro (bacterial reverse mutation, chromosomal aberration in Chinese hamster lung cells) and in vivo (mouse bone marrow micronucleus) assays.”
✓ VerifiedUS prescribing informationSource ↗
Genotox: in vitro mammalian
Chromosomal aberration in Chinese hamster lung cells: negative
“Viltolarsen was negative for genotoxicity in in vitro (bacterial reverse mutation, chromosomal aberration in Chinese hamster lung cells) and in vivo (mouse bone marrow micronucleus) assays.”
✓ VerifiedUS prescribing informationSource ↗
Genotox: in vivo
Mouse bone marrow micronucleus: negative
“Viltolarsen was negative for genotoxicity in in vitro (bacterial reverse mutation, chromosomal aberration in Chinese hamster lung cells) and in vivo (mouse bone marrow micronucleus) assays.”
✓ VerifiedUS prescribing informationSource ↗
Carcinogenicity model
Not conducted; SPA protocols for 26-week Tg.rasH2 mouse and 2-year rat reviewed by the Division and Executive CAC
“Protocols for a 26-week study in Tg.rasH2 mouse and a 2-year study in rat were submitted for review under Special Protocol Assessment and were reviewed by the Division and the Executive CAC under IND 127474 (Minutes dated July 12, 2018, and August 9, 2019, respectively).”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Carcinogenicity timing
Not conducted before approval; 26-week Tg.rasH2 mouse and 2-year rat studies are postmarketing requirements
“If the application is approved, a 26-week carcinogenicity study in Tg.rasH2 mouse and a 2-year carcinogenicity study in rat should be conducted as PMRs.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
hERG / QT
No hERG/QT effect in CHO cells up to 3 mg/mL; no effects in rat CNS and monkey CV/respiratory studies
“Dedicated single dose studies in rat (CNS) and monkey (cardiovascular and respiratory) did not indicate drug effects on safety pharmacology endpoints, and there was no effect on QT prolongation in CHO cell cultures exposed to up to 3 mg/mL vitolarsen.”
✓ VerifiedFDA pharmacology/toxicology review, p. 47Source ↗

Same question, other oligonucleotides

Amondys 45

casimersen · DMD exon 45 (PMO)
Conducted; negative (Ames, CHO chromosomal aberration, mouse micronucleus)

Amvuttra

vutrisiran · TTR (siRNA)
Conducted: Ames, human lymphocyte chromosome aberration, rat micronucleus; all negative

Dawnzera

donidalorsen · Prekallikrein / KLKB1 (ASO)
Conducted: in vitro Ames, CHL chromosomal aberration and in vivo mouse bone marrow micronucleus; no genotoxicity

Defitelio

defibrotide · Fragmented DNA oligonucleotides
Negative: Ames assay and in vivo rat bone marrow micronucleus assay

Exondys 51

eteplirsen · DMD exon 51 (PMO)
Conducted; negative (Ames, CHO chromosomal aberration, mouse micronucleus)

Givlaari

givosiran · ALAS1 (siRNA)
Conducted: Ames, human lymphocyte chromosome aberration, rat micronucleus; all negative

Hibsago

bepirovirsen · HBV RNA (ASO)
Conducted; negative (Ames, mammalian cell chromosomal aberration, in vivo mouse micronucleus)

Izervay

avacincaptad pegol · C5 (aptamer)
Conducted: Ames, chromosomal aberration in mammalian cells, mouse micronucleus; all negative

Kynamro

mipomersen · APOB (ASO)
Conducted; negative (Ames, mouse lymphoma, mouse micronucleus)

Leqvio

inclisiran · PCSK9 (siRNA)
Conducted: standard panel, negative

Macugen

pegaptanib · VEGF-165 (aptamer)
Conducted (GLP); pegaptanib and 2'-FU/2'-FC nucleosides negative overall

Onpattro

patisiran · TTR (siRNA)
Conducted: Ames, human lymphocyte chromosome aberration, mouse micronucleus; all negative

Oxlumo

lumasiran · HAO1 (siRNA)
Conducted: Ames, human lymphocyte chromosome aberration, rat micronucleus; all negative

Qalsody

tofersen · SOD1 (ASO)
Conducted; negative (Ames, CHL chromosomal aberration, mouse micronucleus)

Qfitlia

fitusiran · Antithrombin / SERPINC1 (siRNA)
Conducted: bacterial reverse mutation, in vitro chromosomal aberration (human lymphocytes), rat bone-marrow micronucleus; all negative

Redemplo

plozasiran · APOC3 (siRNA)
Conducted: Ames, in vitro chromosomal aberration (TK6), in vivo mouse micronucleus; not genotoxic

Rivfloza

nedosiran · LDHA (siRNA)
Conducted; negative (Ames, in vitro micronucleus, in vivo mouse micronucleus)

Rytelo

imetelstat · Telomerase (oligo)
Conducted; negative (Ames, in vitro micronucleus, in vivo mouse micronucleus)

Spinraza

nusinersen · SMN2 (ASO)
Conducted; negative (Ames, CHO chromosomal aberration, mouse micronucleus)

Tegsedi

inotersen · TTR (ASO)
Conducted; negative (Ames, CHL chromosomal aberration, mouse micronucleus)

Tryngolza

olezarsen · APOC3 (ASO)
Conducted; negative (Ames, chromosomal aberration, mouse micronucleus)

Vitravene

fomivirsen · CMV IE2 mRNA (ASO)
Conducted: mutagenic potential evaluated in in vitro and in vivo assays

Vyondys 53

golodirsen · DMD exon 53 (PMO)
Conducted; negative (Ames, CHO chromosomal aberration, mouse micronucleus)

Wainua

eplontersen · TTR (ASO)
Conducted; negative (Ames, chromosomal aberration, mouse micronucleus)

Waylivra

volanesorsen · APOC3 (ASO)
Conducted: bacterial reverse mutation, mouse lymphoma TK, mouse bone-marrow micronucleus; all negative

Zanvastro

zilganersen · GFAP (ASO)
Conducted: Ames, in vitro chromosomal aberration, mouse micronucleus; all negative

Summary across all 27 oligonucleotides →